biostudies-literatureUnknown104(9)Kucukyurt SPrimary mediastinal B-cell lymphoma (PMBCL) is a rare and distinct subtype of non-Hodgkin lymphoma. No consensus exists on optimal frontline treatment, and the use of R-CHOP ± radiotherapy (RT) and DA-EPOCH-R ± RT remains common, yet comparative real-world data are limited. In our multicenter retrospective study, we analyzed PMBCL patients, stratified by the first-line therapy (R-CHOP-21 ± RT or DA-EPOCH-R ± RT). Primary outcomes were complete response (CR) rate, progression-free survival (PFS), and overall survival (OS), alongside assessment of treatment-related toxicities and prognostic factors for PFS and OS. We included 157 patients [R-CHOP ± RT group (n = 80) and DA-EPOCH-R ± RT group (n = 77)] with a median age of 31 years, of whom 68.2% were female. CR rates were similar for R-CHOP Annals of hematology4679-4690https://www.ebi.ac.uk/biostudies/studies/S-EPMC12552371biostudies-literatureReal-world outcomes and prognostic factors in primary mediastinal B-cell lymphoma: a multicenter study of 157 patients.PMC12552371Dogan ADilek IAkın SUnal AYigitbası AYeral MTerzi Demirsoy EKeklik Karadag FKucukyurt SGoren DIpek YKaygusuz Atagunduz ICiftciler ROzgur YKurt Yuksel MErdogan Ozunal ISahin FYıldız AUysal ABarısta IKoca OBaysal MSahin OGunes AKUgur MCSalim OSelim CYuksel MAfacan Ozturk HBTıglıoglu PGuven SSaydam GAyer MTaser Kanat NPınar IEIltar UDemir AMAtalay FSoyer Kosemehmetoglu OMehtap OBirtas Atesoglu EEskazan AEUlukoylu Menguc MSoyer NfalseReal-world outcomes and prognostic factors in primary mediastinal B-cell lymphoma: a multicenter study of 157 patients.Primary mediastinal B-cell lymphoma (PMBCL) is a rare and distinct subtype of non-Hodgkin lymphoma. No consensus exists on optimal frontline treatment, and the use of R-CHOP ± radiotherapy (RT) and DA-EPOCH-R ± RT remains common, yet comparative real-world data are limited. In our multicenter retrospective study, we analyzed PMBCL patients, stratified by the first-line therapy (R-CHOP-21 ± RT or DA-EPOCH-R ± RT). Primary outcomes were complete response (CR) rate, progression-free survival (PFS), and overall survival (OS), alongside assessment of treatment-related toxicities and prognostic factors for PFS and OS. We included 157 patients [R-CHOP ± RT group (n = 80) and DA-EPOCH-R ± RT group (n = 77)] with a median age of 31 years, of whom 68.2% were female. CR rates were similar for R-CHOP 2025-01-01T00:00:00Z2025 Sep2026-06-05T04:50:25.756Z2026-05-13T14:29:17.987ZS-EPMC125523714107498210.1007/s00277-025-06644-z